Eric van der Putten

Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler.

Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands.

Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands.